Speaker illustration

Mr Sem A O F Rikken

St Antonius Hospital, Nieuwegein (Netherlands (The))

Member of:

European Society of Cardiology

Sem A.O.F. Rikken graduated as MD at the University of Groningen and he's currently pursuing his PhD under supervision of prof. J.M. ten Berg and prof. A.W.J. van 't Hof. He's affiliated with the Cardiovascular Research Insitute of Maastricht (CARIM) and he works primarily at the Center for Platelet Function Studies at the department of Cardiology in the St. Antonius hospital, Nieuwegein, the Netherlands. His PhD research focuses on novel pre-hospital administered antiplatelet therapies in patients with ST-elevation myocardial infarction.

In vitro comparison of platelet aggregation between zalunfiban and selatogrel in healthy donors

Event: ESC Congress 2023

Topic: Antiplatelet Drugs

Session: Antithrombotic therapy in acute coronary syndromes and PCI


The novel subcutaneously administered glycoprotein IIb/IIIa antagonist RUC-4 (Zalunfiban) did not cause thrombocytopenia in the phase 2a study of patients with ST-elevation myocardial infarction

Event: ESC Acute CardioVascular Care 2022

Topic: Pharmacotherapy

Session: Anti-thrombotic management in patients with acute coronary syndromes (ACS)


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb